Cerecor Inc. Announces Initiation of Second CERC-501 Phase 2 Clinical Trial in Smokers

“Does CERC-501 Attenuate Stress-Related Smoking Lapse?” The study is a collaborative effort between Cerecor and Dr. McKee and is supported by funding from the National Institutes of Health (NIH). “Stress is a primary contributor to the maintenance of, and

The post Cerecor Inc. Announces Initiation of Second CERC-501 Phase 2 Clinical Trial in Smokers appeared first on The Center.

Smoking Cessation Feeds